Inovio Pharmaceuticals Inc (NASDAQ:INO)
| 1.66 Delayed Data As of Jan 26 |  -0.09 / -5.14%Today’s Change | 1.38 Today|||52-Week Range 4.32 | +6.41% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $421.6M |
Company Description
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Contact Information
Inovio Pharmaceuticals, Inc. 660 West Germantown Pike Plymouth Meeting Pennsylvania 19462-1111 |
Employees
Shareholders
| Mutual fund holders | 31.06% |
| Other institutional | 16.23% |
| Individual stakeholders | 1.89% |
Top Executives
| Jacqueline E. Shea | President, Chief Executive Officer & Director |
| Peter D. Kies | Chief Financial Officer |
| Kate E. Broderick | Senior Vice President-Research & Development |
| Stephen Kemmerrer | Senior Vice President-Engineering Development |
| Laurent M. Humeau | Chief Scientific Officer |
